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ting medical conditions may worsen and/or perpe-
tuate patients’ symptoms1-3.
The pathogenesis of pain and other manifesta-
tions in FMS is very complex and not well under-
stood. The important question is what type of me-
chanisms explains this disturbing clinical entity.
FMS Predisposition
FMS is mainly characterized by allodynia (painful
response to a normally innocuous stimulus), hype-
ralgesia (extreme reaction to an usually painful sti-
mulus), increased pain persistence and enlarged
referred painful areas.  
Patients with FMS have an abnormal pain expe-
rience due to an altered pain processing4,5. Several
‘peripheral’ (e.g. skin, microvessels, and muscle)
abnormalities were described in FMS. None of the-
se changes are specific of FMS, although most of
them can be responsible for, or related to repetiti-
ve nociceptive inputs, which can trigger a pheno-
menon called neuroplasticity, and may also be in-
volved in the maintenance of these central nervous
system changes4. So, apart from these non-specific
structural and functional peripheral abnormalities,
some undetected peripheral sensitization disor-
ders, or aberrant peripheral nervous transmission
may be considered on FMS mechanisms4. Based
on many very well developed FMS studies, there is
now sufficient evidence to consider a neuropa-
thophysiological basis for the abnormal pain pro-
cessing leading to its increased perception5. 
There are a large number of factors conditioning
the onset and maintenance of FMS. Among these,
genetic circumstances and environmental aspects
are crucial for the development of this condition.
Increasing evidence suggests a genetic predisposi-
tion in FMS. First degree relatives of patients with
FMS have an 8-fold increased risk of developing
this disorder compared to patients with rheuma-
toid arthritis6. The most probable way of transmis-
sion is polygenic7. Among the candidate genes se-
veral studies confirm that those related to seroto-
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Fibromyalgia syndrome (FMS) is a common chro-
nic disorder characterized by diffuse musculoske-
letal pain and fatigue. Pain is referred to soft tissues
(e.g. muscles, tendons, ligaments, bursae) but ap-
parently is not associated with inflammation or any
other morphologic damage or metabolic distur-
bance on peripheral tissues. The etiology of FMS is
unknown and its pathophysiology unclear. Patients
with FMS present a multiplicity of clinical com-
plaints (e.g. chronic musculoskeletal widespread
pain and other painful entities, fatigue, sleep di-
sorders, morning stiffness, cognitive dysfunction,
mood disturbances, irritable bowel syndrome, non-
dermatomal paresthesias and many other less fre-
quent clinical manifestations). In opposition, ex-
cept for tender points, objective signs on physical
examination are absent and all laboratory and ima-
ging diagnostic tests are normal or negative. Seve-
ral medical conditions and diseases (e.g. syste-
mic/inflammatory rheumatic diseases, psychiatric
illnesses, neurologic disorders, and infectious di-
seases) occur frequently with FMS. These coexis-
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nin play a more relevant role in FMS (e.g. seroto-
nin transporter, 5-hydroxytryptamine 2A recep-
tor). According to other data, FMS may be related
to catecholamine (e.g. catecholamine-o-methyl-
transferase), and dopamine (e.g. dopamine D4 re-
ceptor) polymorphism genes8,9. All these monoa-
mines play an important role in both stress res-
ponse and sensory pathway systems. 
In one or multiple life moments some environ-
mental stressors may interact with genetically de-
termined factors. In individuals at risk, FMS may
be precipitated by an external insult (e.g. trauma,
infections, and diseases), an emotional stressor or
psychosocial events. These precipitating factors
may be acute or chronic. After FMS onset its ma-
nifestations can be maintained through perpetua-
ting factors related to lifestyle, professional activity,
physical conditioning, hypervigilance, mood di-
sorders, catastrophizing or coping behaviours10.
Central Pain Mechanisms
The sequence of events causing FMS is not clear,
but it certainly implicates biochemical and meta-
bolic abnormalities. Some of the changes seen in
the CNS (e.g. low levels of serotonin, significant in-
crease of nerve growth factor and elevated con-
centrations of substance P) strongly suggest that
FMS is not a subjective pain condition, contrarily
indicating the presence of an abnormal central
processing of nociceptive pain. In fact, FMS pa-
tients have several central sensitization characte-
ristics11.
Some authors describe FMS in terms of a sen-
sory intensity control disorder as many patients
show a low threshold, not only to pain but also to
other sensitive stimuli, such as noise, odours, fla-
vours and light12.
Repetitive noxious stimulation may result either
in habituation, with reduced painful responses, or
sensitization, with increased algic response. The-
refore, the prolonged and/or intense activity of the
dorsal horn neurons caused by repetitive or sustai-
ned noxious stimulation may result in increased
neuronal response or central sensitization13. This
means that CNS may learn, and therefore may also
change. Thus, chronic pain characteristics change
over time.  Oppositely, pain is able to change CNS
‘response’, which results in a phenomenon called
neuroplasticity11. This neuroplasticity and subse-
quent CNS sensitization includes changes in terms
of function of its various systems (e.g. chemical,
electrophysiological), which causes allodynia and
hyperalgesia11. Central sensitization is a pa-
thophysiologic mechanism that is common to and
unifies the concept for FMS and other related, si-
milar and overlapping syndromes (e.g. chronic he-
adaches, irritable bowel syndrome, temporoman-
dibular disorder, restless legs syndrome, multiple
chemical sensitivity, interstitial cystitis, primary
dysmenorrhoea, “functional” chronic pelvic pain,
depression) without demonstrable structural pa-
thology.
What defines central sensitization is the increa-
sed response to stimulation, which is mediated by
CNS signalling amplification. In order to occur, it
must recruit a mechanism that signals a noxious
response, even if aggression was not harmful14. This
nervous system dysfunction can amplify normal
peripheral pain and this phenomenon may invol-
ve the spinal cord and the thalamus15. Central sen-
sitization involves spontaneous nerve activity, ex-
panded receptive fields – with larger topographic
distribution of pain – and augmented stimulus res-
ponse, such as abnormal temporal summation or
‘wind-up’16,17. ‘Wind-up’ is a central spinal cord me-
chanism in which repetitive noxious stimulation
results in a slow temporal summation that is sen-
sed in humans as increased pain18. Spinal cord am-
plification mechanism of pain is related to tempo-
ral summation of ‘second pain’ or ‘wind-up’. This
‘second pain’ is more sustained and mainly related
to chronic pain, although it may occur in all indi-
viduals it is more intense in patients with FMS19.
During stimuli transmission, as ‘second pain’,
by C fibers, N-methyl-D-aspartate (NMDA) recep-
tors of the second neurons are activated19. NMDA
amplifies calcium influx into dorsal horn neurons,
which leads to nitric oxide synthetase activation.
Nitric oxide synthesis induces the release of subs-
tance P and other neuropeptides of pre-synaptic
neurons, which facilitate hyperalgesia and central
sensitization maintenance20,21. Substance P redu-
ces synaptic excitability threshold and expands no-
ciceptive fields and neuronal activation by non-
nociceptive afferent impulses22.
Dysregulation of descending inhibitory pain
pathways may also be related to algic sensitiza-
tion. In healthy individuals brain signals downre-
gulate spinal cord responses to painful stimuli23.
This modulatory response is also known as diffu-
se noxious inhibitory controls (DNIC)24. In pati-
ents with FMS, pain modulation after application
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of noxious stimulation is absent, and pain facilita-
ting descending pathways may be very relevant25.
Glial cells are known to play an important role
in pain signalling modulation26. Glial cells are ac-
tivated by painful stimuli and pain signalling neu-
rotransmitters. These cells express receptors, not
only for neurotransmitters but also for viruses and
bacteria, and when activated by painful stimulus,
release a group of neuroactive substances like
prostaglandins, leukotrienes, nerve growth factors,
nitric oxide and excitatory amino acids. Astrocytes
and glial cells also release pro-inflammatory
cytokines (e.g. TNF-alpha, interleukin-1 and -6).
All these phenomena can increase signalling and
perception of pain and may cause expansion of
pain fields27,28.
Neurohormonal disturbance in FMS involves
above all dysfunction of the hypothalamic-pitui-
tary-adrenal axis. This axis plays a central role in
physiologic response to stress29. FMS patients have
low 24-hour serum cortisol levels and an abnormal
circadian pattern of cortisol concentration. They
also show blunted serum cortisol response to en-
dogenous CRH, which suggests an abnormal res-
ponse to stress and also an inadequate reaction to
several stressful events30-33.
Growth hormone levels are reduced during
sleep, probably due to the disruption of stage IV
sleep, well documented in the majority of FMS pa-
tients34. Sex hormone secretion is apparently nor-
mal35.
Also, changes in neurotransmitters are certainly
involved in FMS pain aberrant processing. Seroto-
nin is derived from tryptophan, is widely distribu-
ted and has inhibitory effects on several pain path-
ways. Measurements of serum and CNS serotonin
levels have not shown consistent results36,37.
Although investigations on the role of dopami-
ne in FMS mechanism have been neglected there
is an increased body of evidence of a dopamine-
related pathology in FMS patients38.
Evidence of Central Sensitization in FMS
Studies in FMS patients versus healthy controls
clearly showed exaggerated pain responses after
sensory (e.g. thermal) stimulation of healthy tis-
sues39. Intramuscular electrical stimulation (used
to assess the efficacy of temporal summation) cau-
sed more severe pain and larger referred areas in
FMS patients compared to controls40.
Also, compared to controls, FMS patients
showed more intense and long-lasting pain sensa-
tion after painful experience17. This prolonged and
amplified decay supports the presence of central
sensitization22.
In FMS patients, pain inhibitory systems are not
normally recruited, which did not occur in healthy
controls and patients with chronic low back
pain39,41. Also, compared to controls, FMS patients
presented a lack of activation of endogenous inhi-
bitory systems42.
All these investigations suggest that FMS is a di-
sorder of pain sensitivity modulation. These re-
sults are based on patients’ reports of pain, and are
consequently of subjective nature. Therefore, we
must consider whether hypersensitivity is the re-
sult of central mechanisms or the cause of hyper-
vigilance. Nevertheless, we have now objective
data on the existence of central sensitization in
FMS. 
R. Gracely et al used functional magnetic reso-
nance imaging (fMRI) to evaluate the pattern of
cerebral activation during application of painful
pressure, and to determine whether this pattern
was augmented in patients with FMS compared to
controls. They found that comparable subjectively
painful conditions resulted in activation patterns
that were similar in patients and controls, and si-
milar pressures resulted in different regions of acti-
vation and greater effects in patients. To these au-
thors, these results support the claim that FMS is
characterized by cortical or subcortical augmenta-
tion of pain processing43. Two groups of investiga-
tors, JA Desmeules et al (2003) and B Banic et al
(2004) used spinal nociceptive flexion reflex, a spe-
cific physiologic correlation for the objective eva-
luation of central nociceptive pathways. Electrical
stimulation that was used bypass peripheral re-
ceptors. These studies, although indirectly, strong-
ly pointed to the existence of a state of central
hyperexcitability of the nociceptive system in FMS
patients44,45. In December 2008, J Lutz et al pu-
blished in Arthritis and Rheumatism a very interes-
ting study using a combination of two different
magnetic resonance (MR) techniques – MR diffu-
sion-tensor imaging (MR-DTI) and MR of voxel-
based morphometry (MR-VBM) – to determine mi-
crostructure and volume changes in the central
neuronal networks involved in the sensory-discri-
minative and affective-motivational characteris-
tics of pain, anxiety, memory and regulation of
stress response in FMS female patients and healthy
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female controls. Both methods demonstrated a
striking pattern of changes in brain morphology
among patients with FMS. Thalami and thalamo-
cortical tracts and insular regions showed signifi-
cant decreases in fractional anisotropy. In contrast,
post-central gyri, amygdalae, hippocampi, supe-
rior frontal gyri and anterior cingulated gyri pre-
sented increases in fractional anisotropy and de-
creases in gray matter volume. MR-DTI seems to
be more sensitive than MR-VBM regarding visua-
lization of brain microstructural changes in these
patients46.
Other Pathophysiologic Factors
Abnormal function of the autonomic nervous sys-
tem is also suggested in FMS in view of the fol-
lowing findings: 1) orthostatic hypotension and in-
creased pain in response to tilt table testing; 2) in-
creased rest supine heart rate and decreased heart
rate variability reported in both female and male
patients; 3) decreased responsiveness to beta-
adrenergic stimulation in FMS patients (demons-
trated in vitro), and, 4) changes in cardiovascular
regulation that are probably pathologically rele-
vant in FMS and significantly affected by decondi-
tioning47-51.
Quantitative and qualitative sleep disturbances
are very common in FMS patients. Phase-IV sleep
deprivation led to FMS symptoms in healthy con-
trols. All the more prevalent findings on polysom-
nography (e.g. alpha intrusion, fewer sleep spin-
dles, poor sleep efficiency, increase in cycle alter-
nating pattern rate) are also found in normal indi-
viduals and in patients with other disorders. Sleep
abnormalities do not correlate to FMS complaints,
and treatment of sleep problems rarely leads to the
improvement of FMS symptoms52-54.
Psychopathology plays a crucial role in some
but not all patients with FMS. In general, FMS pa-
tients and close family have a larger prevalence of
psychiatric comorbid conditions than controls
with other rheumatic diseases. Nevertheless, most
patients with FMS are not clinically depressed, and
depression is therefore an independent over-
lapping condition55. Only about one third of FMS
patients are clinically depressed at each consulta-
tion and two thirds in all long lasting FMS duration.
Convincing binding factors to link FMS and de-
pression are lacking, but depression is significantly
more common in FMS patients than in patients
with other musculoskeletal disorders56.
Much has been said and written on the connec-
tion between depression and FMS57. Pain and de-
pression share common pathways and neurotrans-
mitters. This is a possible explanation for their re-
ciprocal relationship. In practice, the presence of
depression aggravates pain and vice versa57.  
Cross-sectional studies in FMS patients have
shown increased rates of anxiety and somatiza-
tion, although it was not possible to determine
whether the psychiatric comorbid condition ‘cau-
sed’ FMS in these patients or, on the contrary, the
painful condition resulted in emotional distress58.
Conclusions
Although chronic pain in FMS is perceived in soft
musculoskeletal tissues, any of the abnormalities
described in peripheral structures are specific or
exclusive of this condition. Additionally, there is
an increasing body of evidence suggesting the exis-
tence of an abnormal central pain processing in
FMS. Some of these central dysfunctions could
even be demonstrated in FMS – hyperexcitability
of spinal cord, reduced perfusion of pain-related
brain areas, changes in brain morphology, and high
levels of substance P in CSF.
Several mechanisms may be involved – neuro-
transmitter abnormalities, neurohormonal dys-
function, central sensitization, dysregulation of
descending inhibitory pain pathways – in FMS pa-
thophysiology. All these mechanisms are probably
more concurrent than competitive or exclusive on
pain amplification. Genetic and environmental
factors are ultimate contributors, which predispo-
se individuals to FMS.
Several stressor events are triggering factors to
the onset of FMS clinical manifestations59. Other
conditions like mood and anxiety disorders may
modulate pain processing in FMS patients. Finally,
FMS symptoms can lead to maladaptive beha-
viours and decreased function, which may further
worsen patients’ symptoms.
Much of this knowledge on FMS pathology is
questionable and needs further research with bet-
ter controlled studies to be validated and transfor-
med in solid science. The incomplete understan-
ding of FMS pathophysiology conditions its actual
treatment. FMS symptoms must be pharmacolo-
gically managed, and non-pharmacologic thera-
pies should be used to control dysfunction60.
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